Predicting age-specific dosing of antipsychotics

H. Uchida, B. G. Pollock, Robert Bies, D. C. Mamo

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Antipsychotic medications are the standard of care for both acute and maintenance treatment of schizophrenia, the latter requiring an indefinite treatment across a patients life span. However, dosing and tolerability of antipsychotics have been studied primarily in younger patients, and very limited data are available for age- and phase-specific dosing. This leaves the clinician with no guidance on dose adjustment as patients grow olderan issue of critical importance, especially in light of recent concerns about increased morbidity and mortality associated with antipsychotics.

Original languageEnglish (US)
Pages (from-to)360-362
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume86
Issue number4
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Antipsychotic Agents
Social Adjustment
Standard of Care
Schizophrenia
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Predicting age-specific dosing of antipsychotics. / Uchida, H.; Pollock, B. G.; Bies, Robert; Mamo, D. C.

In: Clinical Pharmacology and Therapeutics, Vol. 86, No. 4, 10.2009, p. 360-362.

Research output: Contribution to journalArticle

Uchida, H. ; Pollock, B. G. ; Bies, Robert ; Mamo, D. C. / Predicting age-specific dosing of antipsychotics. In: Clinical Pharmacology and Therapeutics. 2009 ; Vol. 86, No. 4. pp. 360-362.
@article{93aabc8ae4574837ae2f5a88730fea23,
title = "Predicting age-specific dosing of antipsychotics",
abstract = "Antipsychotic medications are the standard of care for both acute and maintenance treatment of schizophrenia, the latter requiring an indefinite treatment across a patients life span. However, dosing and tolerability of antipsychotics have been studied primarily in younger patients, and very limited data are available for age- and phase-specific dosing. This leaves the clinician with no guidance on dose adjustment as patients grow olderan issue of critical importance, especially in light of recent concerns about increased morbidity and mortality associated with antipsychotics.",
author = "H. Uchida and Pollock, {B. G.} and Robert Bies and Mamo, {D. C.}",
year = "2009",
month = "10",
doi = "10.1038/clpt.2009.133",
language = "English (US)",
volume = "86",
pages = "360--362",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Predicting age-specific dosing of antipsychotics

AU - Uchida, H.

AU - Pollock, B. G.

AU - Bies, Robert

AU - Mamo, D. C.

PY - 2009/10

Y1 - 2009/10

N2 - Antipsychotic medications are the standard of care for both acute and maintenance treatment of schizophrenia, the latter requiring an indefinite treatment across a patients life span. However, dosing and tolerability of antipsychotics have been studied primarily in younger patients, and very limited data are available for age- and phase-specific dosing. This leaves the clinician with no guidance on dose adjustment as patients grow olderan issue of critical importance, especially in light of recent concerns about increased morbidity and mortality associated with antipsychotics.

AB - Antipsychotic medications are the standard of care for both acute and maintenance treatment of schizophrenia, the latter requiring an indefinite treatment across a patients life span. However, dosing and tolerability of antipsychotics have been studied primarily in younger patients, and very limited data are available for age- and phase-specific dosing. This leaves the clinician with no guidance on dose adjustment as patients grow olderan issue of critical importance, especially in light of recent concerns about increased morbidity and mortality associated with antipsychotics.

UR - http://www.scopus.com/inward/record.url?scp=70349451390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349451390&partnerID=8YFLogxK

U2 - 10.1038/clpt.2009.133

DO - 10.1038/clpt.2009.133

M3 - Article

VL - 86

SP - 360

EP - 362

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -